Skip to main content

Month: January 2023

Five Star Bancorp Announces 4th Quarter 2022 Earnings Release Date and Webcast

RANCHO CORDOVA, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — Five Star Bancorp (Nasdaq: FSBC) (“Five Star” or the “Company”) expects to report its financial results for the quarter and year ended December 31, 2022, after the stock market closes on Monday, January 30, 2023. Management will host a live webcast for analysts and investors to review this information at 1:00 PM ET (10:00 AM PT) on January 31, 2023. The live webcast will be accessible from the “News & Events” section of the Company’s website under “Events” at https://investors.fivestarbank.com/news-events/events. Please pre-register for the event using this link. The webcast will be archived on the Company’s website for a period of 90 days. About Five Star BancorpFive Star is a bank holding company headquartered in Rancho Cordova, California. Five Star operates through...

Continue reading

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues

– The Company expects to exceed 2022 full-year guidance for net product revenues – Preliminary net product revenues for the fourth quarter and full-year 2022 are expected to total $235.5 million and $843.3 million, respectively – Preliminary year-end 2022 cash balance of approximately $2.0 billion CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2022 net product revenues as part of their presentation today at the 41st Annual J.P. Morgan Healthcare Conference. Financial Update* (preliminary and unaudited):Fourth quarter 2022 net product revenues are expected to be approximately $235.5 million, a 32% increase over the same period in 2021. Our expected...

Continue reading

Islandsbanki hf.: Preliminary findings of the Financial Supervisory Authority of the Central Bank of Iceland’s inspection into the execution of the Icelandic State’s offering of 22.5% of Íslandsbanki’s share capital

The Bank has received the preliminary findings from the Financial Supervisory Authority of the Central Bank of Iceland (FSA)’s inspection into the execution of the offering by the Icelandic State of a 22.5% stake in the share capital of Íslandsbanki (the “Bank”) that took place in March 2022 (the Offer). The findings indicate the FSA’s view that the Bank may have violated certain laws and regulations applicable to the Bank’s operations. The FSA findings refer to the FSA‘s powers to impose administrative fines and to conclude cases with a settlement. The FSA has agreed, at the Bank’s request, to enter into settlement proceedings. The management of the Bank takes the FSA findings seriously. The Bank expects to submit a response to the FSA‘s findings in the coming weeks. The Bank has already made changes to its rules and procedures following...

Continue reading

Air France-KLM announces the successful issuance of its inaugural sustainability-linked bonds, for a total aggregate amount of €1.0bn

Paris, 9 January 2023 Air France-KLM announces the successful issuance of its inaugural sustainability-linked bonds, for a total aggregate amount of €1.0bnThe offer attracted strong investor interest, with an orderbook around €2.6bn, covering c. 2.6x the size of the bonds. Bonds’ coupons will be indexed on Air France-KLM Group’s target to reduce its well-to-wake scope 1 and 3 jet fuel greenhouse gas (GHG) emissions by 10% per revenue tonne kilometer (RTK) by 2025 compared to 2019, as part of its wider decarbonization roadmap.The proceeds of the bonds will be allocated to partially redeem the outstanding bank loan guaranteed by the French State issued in May 2020. This transaction will contribute to improving Air France–KLM Group’s financial flexibility through debt reprofiling and will provide additional support to its decarbonization...

Continue reading

Banco Santander Chile: Announces fourth quarter 2022 Analyst and Investor Webcast / Conference Call

SANTIAGO, Chile, Jan. 09, 2023 (GLOBE NEWSWIRE) — You are cordially invited to participate in Banco Santander Chile’s (NYSE: BSAC) conference call-webcast on Friday, February 3, 2023 at 9.00 AM (Eastern Time) where we will discuss 4Q 2022 financial results. The Bank’s Officers participating in the conference call are: Emiliano Muratore, CFO, Robert Moreno, Manager of Investor Relations and Claudio Soto, Chief Economist. A question and answer session will follow the presentation. The Earnings report will be published on February 3, 2023 before the market opens. The quiet period begins on January 23. To participate, the webcast presentation can be viewed at: https://mm.closir.com/slides?id=720987 Or please dial in using any of the below numbers: United Kingdom+44 203 984 9844 USA+1 718 866 4614 Austria+43 720 022981 Brazil+556120171549...

Continue reading

Schneider Electric and BitSight announce partnership to improve detection of Operational Technology (OT) cybersecurity exposure

Aims to enhance OT exposure detection capability by identifying misconfigured connected devices Seeks to improve overall security of customers and partners in the OT environmentSchneider Electric, the global leader in the digital transformation of energy management and automation, and BitSight, the leader in detecting and managing cyber risk, today announced a strategic partnership to develop a first-of-its-kind global Operational Technology (OT) Risk Identification and Threat Intelligence capability. In recent years, both opportunistic and advanced cyber threat actors have shown increased willingness to target industrial and operational sites. Schneider Electric and BitSight each see their partnership as an important step in furthering their commitment to improve the security and resilience of their communities – by detecting...

Continue reading

MANUTAN GROUP : Q1 2022/2023 turnover up by 5.8% compared to Q1 2021/2022, at constant exchange rates and days

Gonesse, January 9, 2023 MANUTAN GROUP Q1 2022/2023 turnover up by 5.8% compared to Q1 2021/2022, at constant exchange rates and daysIn thousands of euros December 31, 2022 December 31, 2021Total Turnover 234 508 225 596In Q1 of the 2022/2023 financial year, Manutan Group’s turnover grew by +4.0% compared to the first quarter of the previous financial year. This growth includes a negative currency and day effect of -0.4% and -1.4% respectively (i.e., a turnover growth of +5.8% at constant exchange rates and days). Revenues amounted to 234.5 million euro, compared with 225.6 million euro in the previous year. In terms of its operational areas, the Group’s situation is as follows:In thousands of euros December 31, 2022 December 31, 2021Enterprises 188 968 175 118South 91 172 82 210Centre 48 773 44 320West 30...

Continue reading

Cornerstone Shareholders Approve Arrangement with SolGold

OTTAWA, Jan. 09, 2023 (GLOBE NEWSWIRE) — Cornerstone Capital Resources Inc. (“Cornerstone”) (TSXV:CGP; OTC:CTNXF; FWB:GWN1) is pleased to announce that at a special shareholder meeting held today (the “Meeting”), holders of common shares of Cornerstone (“Cornerstone Shareholders”) voted overwhelmingly in favour of the special resolution (the “Arrangement Resolution”) approving the previously-announced plan of arrangement (the “Arrangement”) pursuant to which SolGold plc (LSE:SOLG; TSX:SOLG) (“SolGold”) will acquire all of the issued and outstanding common shares of Cornerstone (the “Cornerstone Shares”), other than the Cornerstone Shares already held, directly or indirectly, by SolGold. The Arrangement Resolution was approved by 99.98% of the votes cast by Cornerstone Shareholders present at the virtual Meeting or represented by...

Continue reading

Novotech Acquires US-based Drug Development Consulting Firm, CBR International – Expands Drug Development and FDA Regulatory Expertise

SINGAPORE, Jan. 09, 2023 (GLOBE NEWSWIRE) — Novotech, the leading Asia Pacific centered biotech CRO today announced the acquisition of CBR International, a global product development, clinical oversight and strategic regulatory operations group. CBR was founded in 2002 as a consultancy company focused on assisting biotechnology and pharma companies navigate FDA requirements from early-stage development through to approval. CBR adds a group of experts to Novotech to provide US and global regulatory, scientific, quality, and clinical development services. CBR’s specific regulatory expertise and services include long-range Regulatory Strategy and Writing, FDA Representation, eSubmissions, and Scientific Affairs to support requirements for cGMP commercial product development. The acquisition will further strengthen Novotech’s capabilities...

Continue reading

Novotech Acquires European CRO – Strengthens Global Operations

SINGAPORE, Jan. 09, 2023 (GLOBE NEWSWIRE) — Novotech announced today the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech’s global expansion program. EastHORN was established in 2004 and has over 250 employees. The acquisition means biotech clients can access Novotech’s unique and unparalleled suite of early to late-phase CRO services across Europe and the US, with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. Novotech CEO Dr. John Moller said: “This acquisition is a strategic move to further expand our CRO operations and provide biotech clients with in-country expertise across Asia-Pacific, North America,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.